In vitro and in vivo antimalarial activities of the ethanol extract of Erythrina sigmoidea stem bark used for the treatment of malaria in the Western Region of Cameroon

Tientcheu Noutong Jemimah Sandra, Noumedem Anangmo Christelle Nadia, Yamssi Cédric, Gamago Nkadeu Guy-Armand, Mounvera Abdel Azizi, Ngouyamsa Nsapkain Aboubakar Sidiki, Tako Djimefo Alex Kevin, V. Payne, Haibo Hu
{"title":"In vitro and in vivo antimalarial activities of the ethanol extract of Erythrina sigmoidea stem bark used for the treatment of malaria in the Western Region of Cameroon","authors":"Tientcheu Noutong Jemimah Sandra, Noumedem Anangmo Christelle Nadia, Yamssi Cédric, Gamago Nkadeu Guy-Armand, Mounvera Abdel Azizi, Ngouyamsa Nsapkain Aboubakar Sidiki, Tako Djimefo Alex Kevin, V. Payne, Haibo Hu","doi":"10.3389/fpara.2024.1359442","DOIUrl":null,"url":null,"abstract":"Malaria is one of the leading causes of morbidity and/or mortality in tropical Africa. The spread and development of resistance to chemical antimalarial drugs and the relatively high cost of the latter are problems associated with malaria control and are reasons to promote the use of plants to meet healthcare needs to treat malaria. The aim of this study was to evaluate antiplasmodial activities of extracts of Erythrina sigmoidea (Mah quat), which is traditionally used for the treatment of malaria in the western region of Cameroon.The ethanol extract of E. sigmoidea stem bark was obtained through the maceration process using 95% ethanol, while the aqueous extract was prepared by infusion. The in vitro antiplasmodial effect of extracts against P. falciparum chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains was determined using the Trager and Jensen method. On the other hand, the in vivo antimalarial activity of the extract was evaluated in mice infected with Plasmodium berghei strain NK65 using the Peters’ 4-day suppressive test and Ryley test (curative test). A total of 36 mice were used, subdivided into six groups of six mice each: one normal control, a negative control, a positive control, and three other groups for the tested product. Blood samples were collected on the 10th day of each test for hematological parameters.The aqueous extract had an in vitro antiplasmodial activity against the chloroquine-sensitive strain with an IC50 of 29.51 ± 3.63 µg/mL and against the chloroquine-resistant strain with an IC50 of 35.23 ± 3.17 µg/mL. The highest in vitro antiplasmodial activity was observed with the ethanol extract against the chloroquine-sensitive strain with an IC50 of 6.44 ± 0.08 µg/mL and against the chloroquine-resistant strain with an IC50 of 7.53 ± 0.22 µg/mL. The ethanol extract demonstrated suppressive activity in vivo with reduction rates of 87.69%, 86.79%, and 81.08% at doses of 500 mg/kg, 250 mg/kg, and 125 mg/kg, respectively; and curative activity in vivo with reduction rates of 80%, 78.5%, and 77.5% at doses of 500 mg/kg, 250 mg/kg, and 125 mg/kg, respectively. The number of white blood cells in the negative control (44.55 ± 5.02 103/µL) was higher compared to the other groups. As for the red blood cells, we observed a massive destruction of the latter in the infected and untreated group (5.82 ± 1.50 106/µL) compared to the infected and ethanol extract-treated groups (8.74 ± 1.57 106/µL for 500 mg/kg, 7.54 ± 1.77 106/µL for 250 mg/kg, and 8.9 ± 1.50 106/µL for 125 mg/kg).This study provides scientific data on the use of E. sigmoidea by the local population for the treatment of malaria. It shows that E. sigmoidea has antiplasmodial activity, and we also see that there are differences between the parameters that we have in the treated groups and those of the untreated group. However, toxicity tests are necessary to assess its safety.","PeriodicalId":73098,"journal":{"name":"Frontiers in parasitology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in parasitology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fpara.2024.1359442","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Malaria is one of the leading causes of morbidity and/or mortality in tropical Africa. The spread and development of resistance to chemical antimalarial drugs and the relatively high cost of the latter are problems associated with malaria control and are reasons to promote the use of plants to meet healthcare needs to treat malaria. The aim of this study was to evaluate antiplasmodial activities of extracts of Erythrina sigmoidea (Mah quat), which is traditionally used for the treatment of malaria in the western region of Cameroon.The ethanol extract of E. sigmoidea stem bark was obtained through the maceration process using 95% ethanol, while the aqueous extract was prepared by infusion. The in vitro antiplasmodial effect of extracts against P. falciparum chloroquine-sensitive (3D7) and chloroquine-resistant (Dd2) strains was determined using the Trager and Jensen method. On the other hand, the in vivo antimalarial activity of the extract was evaluated in mice infected with Plasmodium berghei strain NK65 using the Peters’ 4-day suppressive test and Ryley test (curative test). A total of 36 mice were used, subdivided into six groups of six mice each: one normal control, a negative control, a positive control, and three other groups for the tested product. Blood samples were collected on the 10th day of each test for hematological parameters.The aqueous extract had an in vitro antiplasmodial activity against the chloroquine-sensitive strain with an IC50 of 29.51 ± 3.63 µg/mL and against the chloroquine-resistant strain with an IC50 of 35.23 ± 3.17 µg/mL. The highest in vitro antiplasmodial activity was observed with the ethanol extract against the chloroquine-sensitive strain with an IC50 of 6.44 ± 0.08 µg/mL and against the chloroquine-resistant strain with an IC50 of 7.53 ± 0.22 µg/mL. The ethanol extract demonstrated suppressive activity in vivo with reduction rates of 87.69%, 86.79%, and 81.08% at doses of 500 mg/kg, 250 mg/kg, and 125 mg/kg, respectively; and curative activity in vivo with reduction rates of 80%, 78.5%, and 77.5% at doses of 500 mg/kg, 250 mg/kg, and 125 mg/kg, respectively. The number of white blood cells in the negative control (44.55 ± 5.02 103/µL) was higher compared to the other groups. As for the red blood cells, we observed a massive destruction of the latter in the infected and untreated group (5.82 ± 1.50 106/µL) compared to the infected and ethanol extract-treated groups (8.74 ± 1.57 106/µL for 500 mg/kg, 7.54 ± 1.77 106/µL for 250 mg/kg, and 8.9 ± 1.50 106/µL for 125 mg/kg).This study provides scientific data on the use of E. sigmoidea by the local population for the treatment of malaria. It shows that E. sigmoidea has antiplasmodial activity, and we also see that there are differences between the parameters that we have in the treated groups and those of the untreated group. However, toxicity tests are necessary to assess its safety.
喀麦隆西部地区用于治疗疟疾的 Erythrina sigmoidea 茎皮乙醇提取物的体内外抗疟活性
疟疾是非洲热带地区发病和/或死亡的主要原因之一。化学抗疟药物抗药性的传播和发展以及后者相对较高的成本是与疟疾控制相关的问题,也是促进使用植物来满足治疗疟疾的医疗保健需求的原因。本研究旨在评估喀麦隆西部地区传统上用于治疗疟疾的 Erythrina sigmoidea(Mah quat)萃取物的抗疟活性。E. sigmoidea 茎皮的乙醇萃取物是用 95% 的乙醇浸泡获得的,而水萃取物则是通过浸泡制备的。萃取物对恶性疟原虫氯喹敏感菌株(3D7)和氯喹抗性菌株(Dd2)的体外抗疟效果采用特拉格和詹森法进行测定。另一方面,采用彼得斯 4 天抑制试验和雷利试验(治愈试验),评估了提取物在小鼠感染伯格氏疟原虫 NK65 株后的体内抗疟活性。共使用了 36 只小鼠,每只小鼠分为六组:一组为正常对照组,一组为阴性对照组,一组为阳性对照组,另外三组为受试产品组。水提取物对氯喹敏感株具有体外抗疟活性,IC50 为 29.51 ± 3.63 µg/mL,对氯喹耐药株的 IC50 为 35.23 ± 3.17 µg/mL。乙醇提取物对氯喹敏感菌株的体外抗疟活性最高,IC50 为 6.44 ± 0.08 µg/mL,对氯喹耐药菌株的 IC50 为 7.53 ± 0.22 µg/mL。乙醇提取物在体内具有抑制活性,剂量为 500 毫克/千克、250 毫克/千克和 125 毫克/千克时,抑制率分别为 87.69%、86.79% 和 81.08%;在体内具有治疗活性,剂量为 500 毫克/千克、250 毫克/千克和 125 毫克/千克时,治疗率分别为 80%、78.5% 和 77.5%。阴性对照组的白细胞数量(44.55 ± 5.02 103/µL)高于其他组。至于红细胞,我们观察到,与感染组和乙醇提取物处理组(500 毫克/千克为 8.74 ± 1.57 106/微升,250 毫克/千克为 7.54 ± 1.77 106/微升,125 毫克/千克为 8.9 ± 1.50 106/微升)相比,未处理组(5.82 ± 1.50 106/微升)的红细胞被大量破坏。这项研究提供了当地人使用 E. sigmoidea 治疗疟疾的科学数据,表明 E. sigmoidea 具有抗疟活性,而且我们还看到治疗组和未治疗组的参数之间存在差异。不过,还需要进行毒性测试,以评估其安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信